로딩 중…
지수 로딩 중…
젠큐릭스
229000· KOSDAQ· Health Care· Health Care Equipment & Services
₩2,350+1.95%
2026-06-19
Price Chart
젠큐릭스+37.83%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 55.06B KRW |
| Revenue | 7.94B KRW |
| Net Income | -2.19B KRW |
| Total Assets | 31.09B KRW |
| Net Assets | 13.99B KRW |
| Employees | 68 |
| Value | |
| P/B | 3.93x |
| P/S | 6.93x |
| FCF Yield | -11.51% |
| Profitability | |
| ROE | -15.65% |
| ROA | -7.04% |
| Op. Margin | -18.79% |
| Revenue Growth | 23.13% |
| Earnings Growth | -132.87% |
| Financial Health | |
| Debt Ratio | 122.16% |
| Total Debt | 10.43B KRW |
| FCF | -6.34B KRW |
| Cash | 169.9M KRW |
| Current Ratio | 0.56x |
| Performance | |
| 1Y Return | 37.83% |
| 1M Return | -5.24% |
| From 52W High | -67.90% |
| 1Y MDD | -65.33% |
| Trading | |
| Volume | 1,355,633 shares |
| Foreign Own. | 2.42% |
| Per Share | |
| EPS | -435 KRW |
| BPS | 597 KRW |
Company Info
Genecurix, established in 2011 as a liquid biopsy-based molecular diagnostic testing technology enterprise, was listed on KOSDAQ in 2020. The company has developed innovative cancer diagnostic solutions, including Asia's first breast cancer prognosis diagnosis GeneSWell BCT, Droplex, and early diagnostic tests HEPA eDX and COLO eDX. Genecurix has acquired a stake in GinoBio to commercialize cfDNA and research CTC technology, fostering collaborations with leading companies in core technological fields. Genecurix is headquartered in Guro-gu, Seoul Metropolitan City.